




Supplementary Figure 1. (A) CD69 surface expression in activated B cells from day-3 cultures. Purified B220⁺GFP⁺ spleen cells were activated with anti-CD40 plus IL4; we analyzed 6 mice per genotype, with similar results. (B) Number of cells in the cultures of B220⁺GFP⁺ cells activated as in **a** ($n = 9$). (C) ELISpot quantification of ASC at the time points indicated. Cells were isolated and activated as **A** ($n = 6$, *** $p < 0.001$). (D) Photograph of IgM ELISpots at day 4. (E) Secreted IgM per ASC ($n = 3$, *** $p < 0.001$). (F) IgM immunoblot of total soluble IgM immunoprecipitated with anti-mouse IgM antibody from the supernatants of day-3 cultures activated as **A**. A second immunoprecipitation was performed to ensure the total precipitation of secreted IgM. Experiment representative of two independent experiments. $n = 6$ for each genotype. The average of ASC per well are shown below.



Supplementary Figure 2. (A) Lack of long-term plasma cell in the BM of immunized *c-myc^{fl/fl}* mice. Single cell suspensions from the BM were prepared and stained with the markers indicated. (B) Absolute numbers of B220^{lo}Syndecan1⁺GFP⁺ cells gated as shown in A ($n = 3$, $*p < 0.05$, $**p < 0.01$). (C) ELISA quantification for TNP-specific Ig levels in the serum of TNP-KLH immunized mice at the time points indicated. (For IgM and IgE $n = 9$; IgG1 $n = 6$; IgG2a $n = 4$).



Supplementary Figure 3. (A) Marginal Zone (MZ) and Follicular B cells (FO) in the spleen of *c-myc*^{fl/fl} and *c-myc*^{fl/+} mice. Single cell suspensions were prepared, stained with anti-CD23 and anti-CD21 antibodies and analyzed by flow cytometry according to their GFP expression. One representative experiment is shown ($n = 3$). (B) Absolute numbers of MZ and FO B cells from a ($n = 3$ for pre-immune; $n = 4$ for TNP-KLH). (C) (D) Immunohistochemistry of spleen cryosections from TNP-KLH immunized mice; Moma identifies the MZ. Cre recombinase, GFP⁺ (*c-myc* deleted B cells), ($n = 4$). (E) H&E of spleen sections from pre-immune mice with the indicated genotype ($n = 3$). (F) % of FO or MZ cells within the GFP⁺ population (*c-myc* deleted B cells) from the mice showed in A (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$).



Supplementary Figure 4. (A), GL-7 surface expression in spleen B cells from TNP-KLH immunized mice. GFP⁺ (*c-myc* deleted B cells). One representative experiment is shown ($n = 3$). (B) Absolute numbers of GL-7^{hi} cells gated as shown in A. Pre-immune: *c-myc^{fl/+}*, $n = 5$; *c-myc^{fl/fl}*, $n = 3$ (** $p < 0.01$); TNP-KLH: *c-myc^{fl/+}* and *c-myc^{fl/fl}*, $n = 4$ (* $p < 0.05$). C and D *aicda* and *c-myc* gene expression in B cells activated with anti-CD40 plus interleukin-4. Sorted B cells from the spleens of mice with the indicated genotype were isolated ($n = 3$, *** $p < 0.001$). (E) Germline transcripts in cells activated with LPS ($n = 6$, * $p < 0.05$). Black boxes, control mice. (F) Flow cytometry analysis of sorted B220⁺GFP⁺ spleen cells of *c-myc^{fl/fl}*, *c-myc^{fl/+}* and *c-myc^{fl/fl}; Igκ-AID* mice activated as in A ($n = 3$). (G) Luciferase reporter assays in M12 B cell line. Cell were transfected with the constructs shown in Fig. 6, and a *c-Myc* expressing vector. Luciferase activity was measured and normalization was performed as described in methods ($n = 3$, *** $p < 0.001$). RLU, Relative Luciferase Units.